Home/Pipeline/Next-Gen Drug-Eluting Stents

Next-Gen Drug-Eluting Stents

Coronary Artery Disease

DevelopmentActive

Key Facts

Indication

Coronary Artery Disease

Phase

Development

Status

Active

Company

Translumina

About Translumina

Translumina is a privately held, commercial-stage medical device company specializing in interventional cardiology products. With a global manufacturing footprint and a portfolio centered on drug-eluting stents and balloons, the company has established a significant presence, particularly in India and other emerging markets. Its strategy combines in-house R&D with strategic acquisitions, such as Blue Medical Devices, to expand its technology portfolio and geographic reach. The company is positioned in the large and growing cardiovascular devices market, competing on quality, innovation, and cost-effectiveness.

View full company profile

Therapeutic Areas

Cardiovascular

Other Coronary Artery Disease Drugs

Drug	Company	Phase	Status
MUTI™ Drug‑Eluting Stent	Meril	Commercial	Active
Coronary Artery Bypass Grafts	Vascudyne	Pre-clinical	Active
Premier DES	Relisys Medical Devices	Commercial	Active
Release R DES	Relisys Medical Devices	Commercial	Active
Pristine DES	Relisys Medical Devices	Commercial	Active
BioMatrix family (Flex/Alpha)	Biosensors International	Commercial	Marketed
Coronary Artery Disease Program	Elixir Medical	Pre-clinical	Active
Essential pro Stent	iVascularU	Post-Market	Active
FGF-1	Zhittya Genesis Medicine	Phase 2	Active
OMT-28	OMEICOS Therapeutics	Phase 2	Planned
Fantom Encore	REVA Medical	Commercial	Active
Geographic Market Expansion	Translumina	Commercial	Active